摘要
1文献来源Im SA,Lu YS,Bardia A,et al.Overall survival with ribociclib plus endocrine therapy in breast cancer[J].N Engl J Med,2019,381(4):307-316.2证据水平1b。3背景年轻乳腺癌(<50岁)患者在所有乳腺癌患者中占比很高,且这部分患者中大约三分之二是激素受体(hormone receptor,HR)阳性(定义为雌激素或孕激素受体表达,或两者都表达).
作者
杨梅
黄帅
舒茂
YANG Mei;HUANG Shuai;SHU Mao(Department of Breast Cancer,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China)
出处
《循证医学》
2023年第2期78-82,共5页
The Journal of Evidence-Based Medicine
